Article
Landscape of driver mutations and their clinical effects on Down syndrome-related myeloid neoplasms.
Blood - 20 Jun 2024
Sato Tomohiko, Yoshida Kenichi, Toki Tsutomu, Kanezaki Rika, Terui Kiminori, Saiki Ryunosuke, Ojima Masami, Ochi Yotaro, Mizuno Seiya, Yoshihara Masaharu, Uechi Tamayo, Kenmochi Naoya, Tanaka Shiro, Matsubayashi Jun, Kisai Kenta, Kudo Ko, Yuzawa Kentaro, Takahashi Yuka, Tanaka Tatsuhiko, Yamamoto Yohei, Kobayashi Akie, Kamio Takuya, Sasaki Shinya, Shiraishi Yuichi, Chiba Kenichi, Tanaka Hiroko, Muramatsu Hideki, Hama Asahito, Hasegawa Daisuke, Sato Atsushi, Koh Katsuyoshi, Karakawa Shuhei, Kobayashi Masao, Hara Junichi, Taneyama Yuichi, Imai Chihaya, Hasegawa Daiichiro, Fujita Naoto, Yoshitomi Masahiro, Iwamoto Shotaro, Yamato Genki, Saida Satoshi, Kiyokawa Nobutaka, Deguchi Takao, Ito Masafumi, Matsuo Hidemasa, Adachi Souichi, Hayashi Yasuhide, Taga Takashi, Saito Akiko M, Horibe Keizo, Watanabe Kenichiro, Tomizawa Daisuke, Miyano Satoru, Takahashi Satoru, Ogawa Seishi, Ito Etsuro
Abstract excerpt
ABSTRACT: Transient abnormal myelopoiesis (TAM) is a common complication in newborns with Down syndrome (DS). It commonly progresses to myeloid leukemia (ML-DS) after spontaneous regression. In contrast to the favorable prognosis of primary ML-DS, patients with refractory/relapsed ML-DS have poor outcomes. However, the molecular basis for refractoriness and relapse and the full spectrum of driver mutations in...
Topics
Join the communities discussing this publication.